ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1142

A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL

Meeting: ACR Convergence 2023

Keywords: Autoantibody(ies), Biomarkers, interstitial lung disease, prognostic factors, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but there remains a lack of substantial data on the association of some autoantibodies present in scleroderma patients with specific ILD patterns. We sought to investigate possible association, describe the phenotypes of scleroderma seen in our study cohort, and review findings from other studies.

Methods: The cohort included adults with scleroderma and ILD who were treated at Mayo Clinic between January 2011 and December 2021. Baseline demographic, serologic, and imaging data were extracted from the electronic medical record. Continuous variables were summarized with median and range, and categorical variables were summarized with frequency and percentage (%). The Kruskal-Wallis Rank Sum test was used for continuous measures and the Chi-square test was used for categorical measures. All tests were two-sided and p-values less than 0.95 were considered to be statistically significant. Analysis programming was performed by R-studio with R version 4.1.2.

Results: A total of 454 patients with both scleroderma and ILD were included in the study. The study cohort had a mean age of 62 years, and 103 patients (22.7%) were males. ILD patterns analyzed included NSIP (83.3%), UIP (11%), probable UIP (2.9%), indefinite UIP (2.9%), OP (1.5%) and LIP (2%). The antibody and symptoms were determined for patients with and without each of these ILD patterns. NSIP patients were more likely to have anti-Scl70 antibodies compared to patients without NSIP ( p=0.01). OP patients were more likely to have anti-PM/Scl antibodies compared to patients without OP (p=0.006), and LIP patients were more likely to have anti-U1 snRNP antibodies compared to patients without LIP (p=0.002). LIP patients were significantly less likely to have antiScl70 antibodies than patients without LIP (p=0.025). Additionally, UIP patients were also less likely to have anti-Scl70 antibodies than patients without UIP (p=0.017). There were no clinically significant findings of anti-centromere antibodies or anti-RNA Pol III antibodies in any of the ILD patterns. No symptoms had a clinically significant association with the ILD pattern groups.

Conclusion: Our study examined associations between serologic data and ILD patterns and demonstrated a statistically significant association of anti-Scl70 antibodies with NSIP and antiPM/Scl antibodies with OP. There also appears to be an association between anti-U1 snRNP antibodies and LIP, which has not been demonstrated in the literature thus far aside from another observational study. LIP and UIP patterns were significantly less likely to have association with anti-Scl70 antibodies. We did not find any statistically significant association between anticentromere antibodies and specific ILD patterns. Finally, our study suggests that antibodies may develop in scleroderma but are not necessarily associated with development of ILD. Autoantibodies offer an invaluable tool in predicting disease outcomes and further studies are needed to elucidate this, especially with regards to scleroderma-associated ILD.

Supporting image 1

Table 1A: Frequency of percentage of antibodies and symptoms by ILD pattern

Supporting image 2

Table 1B: Frequency and percentage of ILD pattern by antibody and symptom group

Supporting image 3

Supplementary table 1: Summary of demographic descriptions


Disclosures: N. Jhawar: None; C. Wilson: None; A. Abril: None; L. Zhuo: None; Y. Ma: None.

To cite this abstract in AMA style:

Jhawar N, Wilson C, Abril A, Zhuo L, Ma Y. A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-retrospective-analysis-of-radiographic-and-serologic-findings-in-patients-with-scleroderma-and-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-retrospective-analysis-of-radiographic-and-serologic-findings-in-patients-with-scleroderma-and-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology